T · 4892.T
Cyfuse Biomedical K.K.
- Sector
- Healthcare · Drug Manufacturers - Specialty & Generic
- Headquarters
- Tokyo 108-6301
- Website
- cyfusebio.com
Price · as of 2025-12-31
$678.00
Market cap 5.44B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $352.45 | -48.02% |
| Intrinsic Value(DCF) | $375.88 | -44.56% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | $5,224.06 | $115,716.86 | |||
| 2022 | $1,160.00 | $1,598.70 | $1,159.49 | $524.81 | $6,576.98 |
| 2023 | $768.00 | $381.32 | $313.08 | $32.95 | $5,417.90 |
| 2024 | $1,122.00 | $482.79 | $183.17 | $0.00 | $259.08 |
| 2025 | $639.00 | $352.45 | $200.69 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Cyfuse Biomedical K.K.'s (4892.T) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $352.45
- Current price
- $678.00
- AI upside
- -48.02%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$375.88
-44.56% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
About Cyfuse Biomedical K.K.
Cyfuse Biomedical K.K. engages in the development, manufacture, and sale of regenerative medicine products in Japan. It develops cellular products in the field of regenerative therapy; and undertakes contract for cellular products for research and development. The company also offers Bio 3D Printer for use in the regeneration of various tissues and organs, such as cartilage and bones, blood vessels, and nerves; regenova, a bio 3D printer for 3D stacking of cells; and S-PIKE that develops 3D-structures from cells. Cyfuse Biomedical K.K. was incorporated in 2010 and is based in Tokyo, Japan.
- CEO
- Shizuka Akieda
- Employees
- 21
- Beta
- 1.54
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($375.88 ÷ $678.00) − 1 = -44.56% (DCF, example).